The COVAX initiative for equitable global access to COVID-19 vaccines has published its first distribution list, planning enough doses for dozens of countries to immunise more than 3 percent of their populations by mid-year.
The release of the “interim distribution forecast” on Wednesday came amid concerns over whether lower-income countries will be left out of the immunisation race dominated by rich nations – a problem COVAX, which is led by the United Nations-backed vaccine alliance Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), was set up to resolve.
The list broke down for the first time how the programme’s initial 337.2 million doses will be distributed, in line with a target “to protect the most vulnerable groups such as health care workers” in the first half of the year.
<div class="at-above-post addthis tool" data-url="https://www.metro.us/novavax-says-covid-19-vaccine/"></div>CHICAGO (Reuters) – Novavax Inc said on Thursday its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK, according to a preliminary analysis. A mid-stage trial of the vaccine in […]<! AddThis Advanced Settings above via filter on get the excerpt ><! AddThis Advanced Settings below via filter on get the excerpt ><! AddThis Advanced Settings generic via filter on get the excerpt ><! AddThis Share Buttons above via filter on get the excerpt ><! AddThis Share Buttons below via filter on get the excerpt ><div class="at-below-post addthis tool" data-url="https://www.metro.us/novavax-says-covid-19-vaccine/"><
Novavax Inc said on Thursday its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK, according to a preliminary analysis.
Vials with a sticker reading, COVID-19 / Coronavirus vaccine / Injection only and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
Novavax Inc said on Thursday its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK, according to a preliminary analysis.
A mid-stage trial of the vaccine in South Africa, where a troubling new variant of the virus is common, showed 60% effectiveness among people who did not have HIV.
Novavax Inc. said Thursday its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the U.K., according to a preliminary analysis.